249 related articles for article (PubMed ID: 26768506)
1. Saving orphan drug legislations: misconceptions and clarifications.
Hyry HI; Cox TM; Roos JC
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):111-7. PubMed ID: 26768506
[TBL] [Abstract][Full Text] [Related]
2. Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation.
Tu SS; Nagar S; Kesselheim AS; Lu Z; Rome BN
JAMA; 2023 May; 329(18):1607-1608. PubMed ID: 37159041
[TBL] [Abstract][Full Text] [Related]
3. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
4. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
5. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
6. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
7. What is wrong with orphan drug policies?
Côté A; Keating B
Value Health; 2012 Dec; 15(8):1185-91. PubMed ID: 23244823
[TBL] [Abstract][Full Text] [Related]
8. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
9. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
Guan X; Zhang J; Man C; Ni B; Shi L
J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
[TBL] [Abstract][Full Text] [Related]
10. [European ordinance on orphan drugs: changes and threats].
Linthorst GE; Hollak CE
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
[TBL] [Abstract][Full Text] [Related]
11. Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union.
Żelewski P; Wojna M; Sygit K; Cipora E; Gąska I; Niemiec M; Kaczmarski M; Banaś T; Karakiewicz B; Kotwas A; Zabielska P; Partyka O; Pajewska M; Krzych-Fałta E; Bandurska E; Ciećko W; Czerw A
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231399
[TBL] [Abstract][Full Text] [Related]
12. The Orphan Drug Act. The first 7 years.
Asbury CH
JAMA; 1991 Feb; 265(7):893-7. PubMed ID: 1992188
[TBL] [Abstract][Full Text] [Related]
13. [Orphan drugs and drug pirates].
Bannenberg WJ; 't Hoen EFM
Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749801
[TBL] [Abstract][Full Text] [Related]
14. Economic considerations in the provision of treatments for rare diseases.
McCabe C; Edlin R; Round J
Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
[TBL] [Abstract][Full Text] [Related]
15. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
16. Getting to the Root of High Prescription Drug Prices.
Waxman H; Corr B; Martin K; Duong S
Issue Brief (Commonw Fund); 2017 Jul; 2017():1-10. PubMed ID: 28700190
[TBL] [Abstract][Full Text] [Related]
17. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
Kawakami A; Masamune K
Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
[TBL] [Abstract][Full Text] [Related]
18. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
Danzon PM
Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
[TBL] [Abstract][Full Text] [Related]
19. Orphan drugs: the question of products liability.
Scharf SF
Am J Law Med; 1985; 10(4):491-513. PubMed ID: 3911776
[TBL] [Abstract][Full Text] [Related]
20. New products highlight ambiguity of orphan drug law.
Reid B
Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896
[No Abstract] [Full Text] [Related]
[Next] [New Search]